TRCT
GSK icon

Tower Research Capital (TRC)’s GSK GSK Stock Holding History

Tower Research Capital (TRC)’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3M Buy
463,125
+87,131
+23% +$4.61M 0.59% 29
2026
Q1 		$20.8M Buy
375,994
+146,782
+64% +$7.95M 0.54% 23
2025
Q4 		$11.2M Buy
229,212
+209,102
+1,040% +$9.75M 0.27% 60
2025
Q3 		$868K Buy
20,110
+17,010
+549% +$664K 0.02% 574
2025
Q2 		$119K Sell
3,100
-11,727
-79% -$448K ﹤0.01% 2240
2025
Q1 		$574K Buy
14,827
+14,241
+2,430% +$521K 0.02% 758
2024
Q4 		$19.8K Sell
586
-24,468
-98% -$881K ﹤0.01% 3188
2024
Q3 		$1.02M Sell
25,054
-4,081
-14% -$167K 0.03% 521
2024
Q2 		$1.12M Buy
29,135
+19,919
+216% +$838K 0.02% 701
2024
Q1 		$395K Buy
9,216
+5,422
+143% +$224K 0.01% 1001
2023
Q4 		$141K Buy
3,794
+3,077
+429% +$110K ﹤0.01% 2365
2023
Q3 		$26K Sell
717
-1,392
-66% -$49.4K ﹤0.01% 3140
2023
Q2 		$75.2K Buy
2,109
+824
+64% +$29.6K ﹤0.01% 2257
2023
Q1 		$46K Sell
1,285
-1,710
-57% -$59.8K ﹤0.01% 2566
2022
Q4 		$105K Sell
2,995
-16,484
-85% -$549K ﹤0.01% 1799
2022
Q3 		$573K Buy
19,479
+15,721
+418% +$596K 0.01% 1037
2022
Q2 		$204K Buy
3,758
+3,756
+187,800% +$207K ﹤0.01% 1761
2022
Q1 		$0 Sell
2
-2,320
-100% -$126K ﹤0.01% 6265
2021
Q4 		$128K Buy
+2,322
New +$121K ﹤0.01% 2068
2021
Q3 		– Sell
-6,124
Closed -$305K – 5915
2021
Q2 		$305K Sell
6,124
-473
-7% -$22.7K 0.01% 1593
2021
Q1 		$295K Sell
6,597
-10,636
-62% -$483K 0.01% 1676
2020
Q4 		$793K Buy
17,233
+15,883
+1,177% +$730K 0.02% 649
2020
Q3 		$64K Buy
1,350
+1,161
+614% +$58.2K ﹤0.01% 3430
2020
Q2 		$10K Sell
189
-10,098
-98% -$518K ﹤0.01% 4008
2020
Q1 		$487K Buy
10,287
+10,073
+4,707% +$537K 0.03% 439
2019
Q4 		$13K Sell
214
-4,249
-95% -$236K ﹤0.01% 2201
2019
Q3 		$238K Buy
4,463
+3,301
+284% +$170K 0.02% 916
2019
Q2 		$58K Sell
1,162
-7,192
-86% -$361K ﹤0.01% 1503
2019
Q1 		$437K Buy
8,354
+8,274
+10,343% +$413K 0.03% 678
2018
Q4 		$4K Sell
80
-2,306
-97% -$114K ﹤0.01% 3029
2018
Q3 		$119K Sell
2,386
-354
-13% -$18K 0.01% 1246
2018
Q2 		$138K Sell
2,740
-16,831
-86% -$848K 0.01% 1242
2018
Q1 		$956K Buy
19,571
+19,411
+12,132% +$904K 0.08% 206
2017
Q4 		$7K Buy
160
+80
+100% +$3.7K ﹤0.01% 2737
2017
Q3 		$4K Sell
80
-381
-83% -$19.3K ﹤0.01% 3392
2017
Q2 		$25K Sell
461
-780
-63% -$41.6K ﹤0.01% 1101
2017
Q1 		$65K Buy
1,241
+1,214
+4,496% +$61.6K 0.01% 623
2016
Q4 		$1K Sell
27
-2,085
-99% -$103K ﹤0.01% 3607
2016
Q3 		$114K Buy
2,112
+570
+37% +$31.3K 0.01% 744
2016
Q2 		$84K Buy
1,542
+1,263
+453% +$66.5K 0.01% 1217
2016
Q1 		$14K Buy
+279
New +$13.9K ﹤0.01% 1622
2015
Q4 		– Sell
-608
Closed -$29K – 4685
2015
Q3 		$29K Buy
608
+470
+341% +$24.5K ﹤0.01% 1427
2015
Q2 		$7K Buy
138
+134
+3,350% +$7.54K ﹤0.01% 2994
2015
Q1 		$0 Buy
+4
New +$229 ﹤0.01% 4607
2014
Q4 		– Sell
-372
Closed -$22K – 4271
2014
Q3 		$22K Buy
372
+212
+133% +$13K ﹤0.01% 2226
2014
Q2 		$11K Sell
160
-3,402
-96% -$230K ﹤0.01% 2279
2014
Q1 		$238K Buy
3,562
+2,589
+266% +$175K 0.03% 365
2013
Q4 		$65K Sell
973
-153
-14% -$9.92K 0.01% 1177
2013
Q3 		$70K Buy
1,126
+678
+151% +$43.6K 0.01% 1617
2013
Q2 		$28K Buy
+448
New +$28.4K ﹤0.01% 1398

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Tower Research Capital (TRC)'s GSK Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its GSK (GSK) stake by 23% in Q2 2026, buying an estimated $4.61M and bringing the position to 463,125 shares worth $24.3M. The position accounts for 0.59% of the portfolio, ranked #29.

Tower Research Capital (TRC) first reported a position in GSK in Q2 2013 and has held it in 50 quarters since. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Tower Research Capital (TRC) held 463,125 shares of GSK worth $24.3M as of Q2 2026.
  • Tower Research Capital (TRC) bought 87,131 GSK shares in Q2 2026, an estimated $4.61M.
  • GSK made up 0.59% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #29 holding.
  • Tower Research Capital (TRC) first reported a position in GSK in Q2 2013 and has held it in 50 quarters since.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.